Evidence map›Paper›PMID 31105954›Full record

ArticleSAGE open medical case reports2019

Resolution of new daily persistent headache by a tumor necrosis factor alpha antagonist, Venlafaxine.

Zeshan Tariq, Nathan Board, Alex Eftimiades, Ronnie Ibrahim

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Role of TNFPain research & management · 2024
    Review
  3. Update of New Daily Persistent Headache.Current pain and headache reports · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Zeshan TariqDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-2705-2842
Nathan BoardJohns Hopkins School of Medicine, Baltimore, MD, USA.
Alex EftimiadesUniversity of Maryland, Baltimore County, Baltimore, MD, USA.
Ronnie IbrahimMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USJohns Hopkins University · USUniversity of Maryland, Baltimore County · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New daily persistent headache is a continuous, unremitting headache, notorious for its unresponsiveness to aggressive medical interventions. The underlying pathophysiology of new daily persistent headache is poorly understood resulting in unending, chronic pain. However, a prior study identified elevated tumor necrosis factor alpha within the cerebral spinal fluid of new daily persistent headache patients. Herein, we report on a patient who suffered with headache for 6 years failing to respond to over 20 different medical treatments, but found drastic improvement and eventual resolution with Venlafaxine. This drug binds to the 5-HT

Indexed as

5HT-2aheadacheNDPHNew daily persistent headacheserotoninTNF-alphatumor necrosis factor alphaVenlafaxine

Identifiers

PMID31105954
PMCPMC6503587
OpenAlexW2944689945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.